Doxil®--the first FDA-approved nano-drug: lessons learned.

@article{Barenholz2012DoxiltheFF,
  title={Doxil®--the first FDA-approved nano-drug: lessons learned.},
  author={Yechezkel Chezy Barenholz},
  journal={Journal of controlled release : official journal of the Controlled Release Society},
  year={2012},
  volume={160 2},
  pages={117-34}
}
Doxil®, the first FDA-approved nano-drug (1995), is based on three unrelated principles: (i) prolonged drug circulation time and avoidance of the RES due to the use of PEGylated nano-liposomes; (ii) high and stable remote loading of doxorubicin driven by a transmembrane ammonium sulfate gradient, which also allows for drug release at the tumor; and (iii) having the liposome lipid bilayer in a "liquid ordered" phase composed of the high-T(m) (53 °C) phosphatidylcholine, and cholesterol. Due to… CONTINUE READING
Highly Influential
This paper has highly influenced 35 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Related Discussions
This paper has been referenced on Twitter 10 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 507 extracted citations

Liposomal therapies in oncology: does one size fit all?

Cancer Chemotherapy and Pharmacology • 2018
View 6 Excerpts
Highly Influenced

Analytical ultracentrifugation for analysis of doxorubicin loaded liposomes

International journal of pharmaceutics • 2017
View 5 Excerpts
Highly Influenced

Multi-Approach Design and Fabrication of Hybrid Composites for Drug Delivery and Cancer Therapy

BÁRBARA HERRANZ BLANCO, Bárbara Herranz Blanco, Hélder A Santos, Dean Jouni Hirvonen
2016
View 5 Excerpts
Highly Influenced

Overcoming multidrug resistance with nanomedicines.

Expert opinion on drug delivery • 2015
View 14 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 145 references

Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors.

Proceedings of the National Academy of Sciences of the United States of America • 1988
View 20 Excerpts
Highly Influenced

Doxil—the first FDA-approved nano-drug: from an idea to a product

Y. Barenholz
in: D. Peer (Ed.), Handbook of Harnessing Biomaterials in Nanomedicine: Preparation, Toxicity, and Applications, Pan Stanford Publishing, Singapore • 2012
View 14 Excerpts
Highly Influenced

Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal Doxorubicin

R. Solomon, A. Gabizon
Clin. Lymphoma Myeloma 8 • 2008
View 11 Excerpts
Highly Influenced

Amphipathic weak base loading into preformed liposomes having a transmembrane ammonium ion gradient: From the bench to approved DOXIL

Y. Barenholz
3rd ed., in: G. Gregoriadis (Ed.), Liposome Technology: Entrapment of Drugs and Other Materials into Liposomes, vol. 2, Informa Healthcare, New York • 2007
View 14 Excerpts
Highly Influenced

Method for Drug Loading in Liposomes

A. A. Gabizon, Y. Barenholz
in, International Patent Appl., WO/2005/046643 • 2005
View 5 Excerpts
Highly Influenced

Liposome application: problems and prospects

Y. Barenholz
Curr. Opin. Colloid Interface Sci. 6 • 2001
View 10 Excerpts
Highly Influenced

Handbook of Cancer Chemotherapy

R. T. Skeel
Lippincott Williams & Wilkins, Philadelphia • 1999
View 4 Excerpts
Highly Influenced

Rational design of amphiphile-based drug carriers and sterically stabilized carriers

Y. Barenholz, R. Cohen
J. Liposome Res. 5 • 1995
View 8 Excerpts
Highly Influenced

Efficient Loading and Controlled Release of Amphipathic Molecules

Y. Barenholz, G. Haran
in, United States Patent 5,244,544 • 1994
View 6 Excerpts
Highly Influenced

A large-scale method for the preparation of sterile and nonpyrogenic liposomal formulations of defined size distributions for clinical use

S. Amselem, A. Gabizon, Y. Barenholz
in: G. Gregoriadis (Ed.), Liposome Technology, 2nd ed., Liposome Preparation and Related Techniques, vol. 1, CRC Press, Boca Raton, FL • 1993
View 4 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…